31 May 2022
Cambridge Cognition partners on ambitious project for digital measurement of Alzheimer’s disease and related dementia symptoms
Cambridge Cognition is pleased to announce that they have joined the Digital Medicine Society’s (DiMe) Alzheimer’s Disease and Related Dementias (ADRD) Digital Measure Development project. As a partner of this innovative, collaborative effort, Cambridge Cognition will work to harness the potential of digital medicine to advance therapies for ADRD.
13 May 2022
Investigating the Impact of COVID-19 on Cognition
Children of the 90s collaborates with researchers at Cambridge Cognition to investigate the cognitive impacts of COVID-19.
16 December 2021
Electronic Clinical Outcomes Assessment contract win worth over £500,000
Cambridge Cognition is pleased to announce that it has won a contract worth over £500,000 to provide electronic clinical outcome assessments ("eCOA").
9 December 2021
Cambridge Cognition wins £1.0m schizophrenia clinical trial contract
Cambridge Cognition, which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for an additional schizophrenia clinical trial worth £1.0m.
26 October 2021
Cambridge Cognition wins contract for a pivotal schizophrenia trial
Cambridge Cognition, which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for a further sizeable schizophrenia trial with an existing customer.
6 August 2021
Cambridge Cognition: COVID-19 Update
We would like to update you on the steps Cambridge Cognition is taking to ensure business continuity for all our customers as the widespread impact of COVID-19 (coronavirus) continues to affect so many globally.